Omeros Co. (NDAQ:OMER) had its price objective cut by research analysts at Needham & Company LLC from $24.00 to $22.00 in a research note issued on Friday. The firm presently has a “buy” rating on the stock.

Shares of Omeros (NDAQ:OMER) opened at 11.75 on Friday. The stock has a 50 day moving average price of $11.05 and a 200 day moving average price of $10.51. The company’s market capitalization is $504.25 million. Omeros has a 1-year low of $7.20 and a 1-year high of $16.38.

Your IP Address:

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with's FREE daily email newsletter.